Albuminuria During Treatment With Angiotensin Type II Receptor Blocker Is a Predictor for GFR Decline Among Non-Diabetic Hypertensive CKD Patients

PLoS One. 2018 Aug 27;13(8):e0202676. doi: 10.1371/journal.pone.0202676. eCollection 2018.


Background: Albuminuria is a predictor of disease progression in patients with chronic kidney disease (CKD). However, the ability of proteinuria parameters measured at various time periods to predict renal outcomes is unclear.

Method: This observational cohort study included 165 non-diabetic hypertensive CKD patients who took olmesartan medoxomil. We measured the albuminuria at five different time points (0, 2, 4, 26, and 38 months) and the mean levels. The mean albuminuria levels were calculated during 0-4 months, 0-26 months, and 0-38 months. The renal outcome was defined as a decline in eGFR ≥ 40% during the entire study period.

Result: The albuminuria at five different time points and the mean albuminuria levels were independent risk factors for a worse renal outcome after adjusting for age, sex, and estimated glomerular filtration rate (eGFR) at enrollment and were able to predict the renal outcome, although the performance of the estimation tended to be more effective using the mean albuminuria level at the 38-month follow-up time point. The risk of a decline in eGFR ≥ 40% was increased by 1.690-folds [95% CI 1.110-2.572, P = 0.014] per 500 mg/day increase in the mean albuminuria at 38 months. With a cut-off value of 897 mg/day for mean albuminuria at 38 months after treatment, a decline in eGFR ≥ 40% was predicted with a sensitivity of 88.9% and specificity of 81.3%. The ability of albuminuria to predict a renal event at different measurement points does not differ in CKD patients.

Conclusion: The time-averaged albuminuria cut-off of 900 mg/day during the 3-year follow-up period showed high sensitivity and specificity for predicting a decline in eGFR ≥ 40% in CKD patients, although the albuminuria at different measurement points did not predict a worse renal outcome.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Albuminuria / complications
  • Albuminuria / diagnosis*
  • Angiotensin II Type 2 Receptor Blockers / therapeutic use*
  • Area Under Curve
  • Cohort Studies
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Glomerular Filtration Rate
  • Humans
  • Hypertension / complications
  • Hypertension / diagnosis
  • Kidney / physiopathology
  • Male
  • Middle Aged
  • Olmesartan Medoxomil / therapeutic use
  • ROC Curve
  • Renal Insufficiency, Chronic / complications
  • Renal Insufficiency, Chronic / drug therapy*
  • Renal Insufficiency, Chronic / pathology
  • Risk Factors


  • Angiotensin II Type 2 Receptor Blockers
  • Olmesartan Medoxomil

Grant support

This study was funded by Daiichi Sankyo Korea Co. Ltd. and Seoul National University Bundang Hospital (grant number: 02-2017-043). Daiichi Sankyo Korea Co. Ltd. supplied the drug during trial phase. The funder had no role in study design, data collection, interpretation of data and analysis, decision to publish, or preparation of the manuscript.